Quick Takeaways
- Mark Stenhouse has 2 issuer positions tracked on this page.
- Estimated disclosed ownership value: $99,300.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Mark Stenhouse
- Location
- Madison, WI
- Summary
- The estimated net worth of Mark Stenhouse is at least $99,300 dollars as of 05 Jun 2025. Mark Stenhouse is the Director of Phathom Pharmaceuticals, Inc. and owns shares of Phathom Pharmaceuticals, Inc. (PHAT) stock worth about $99.3K.
- Signature
- /s/ Steven Basta, Attorney-in-Fact for Mark Stenhouse
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Mark Stenhouse and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Phathom Pharmaceuticals, Inc. ($99,300).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Mark Stenhouse
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | Director | $99,300 | 03 Jun 2025 | ||
| RXDX | Prometheus Biosciences, Inc. | Chief Operating Officer | 16 Jun 2023 |
Insider Transactions Reported by Mark Stenhouse:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.